Who we are
The Vanishing White Matter Consortium (VWM) consists of 9 (pediatric) neurologists from 8 academic medical centers worldwide, all involved in leukodystrophy patient care and research. Together with our partners, we work towards a cure for VWM.
Our mission is to enable and accelerate therapeutics for Vanishing White Matter, aiming at accessibility and affordability for all patients. To this purpose, we established an international collaboration, which engages partners to provide unbiased analyses of different therapeutics, using smart trial design to address recruitment challenges of this rare disease. We work together with a number of partner organizations, including academic institutes, biotech and pharma companies, and patient and family organizations.
Guanabenz trial for Vanishing White Matter
The Amsterdam Leukodystrophy Center at the Amsterdam University Medical Centers (Amsterdam UMC) is conducting a clinical trial in children with Vanishing White Matter (VWM). In this trial, we want to evaluate whether a drug called Guanabenz is effective in slowing progression, stabilizing, or even improving the brain white matter abnormalities in VWM.
To achieve our mission and work towards a treatment for Vanishing White Matter, our consortium works together with a number of partner organizations, including academic institutes, biotech, and pharma companies, and patient and family organizations.